AR108011A1 - Moduladores receptores de estrógenos - Google Patents
Moduladores receptores de estrógenosInfo
- Publication number
- AR108011A1 AR108011A1 ARP170100788A ARP170100788A AR108011A1 AR 108011 A1 AR108011 A1 AR 108011A1 AR P170100788 A ARP170100788 A AR P170100788A AR P170100788 A ARP170100788 A AR P170100788A AR 108011 A1 AR108011 A1 AR 108011A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- group
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
- C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings
Abstract
Compuestos derivados de indolpirimidina utilizables en el tratamiento del cáncer de mama. Se proveen además, intermediarios para su síntesis. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: X¹, Y¹ y Z¹ son cada uno independientemente C o N; con la primera salvedad de que por lo menos uno de X¹, Y¹ y Z¹ es N; con la segunda salvedad de que cada uno de X¹, Y¹ y Z¹ es neutro; con la tercera salvedad de que dos de las líneas de puntos indican uniones doble; con la cuarta salvedad de que las valencias de X¹, Y¹ y Z¹ puede ser satisfechas cada una independientemente mediante acople a un sustituyente seleccionado de H y R¹²; X² es O, NH o S; A¹ se selecciona del grupo que consiste de un cicloalquilo opcionalmente sustituido, un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido y un heterociclilo opcionalmente sustituido; R¹ se selecciona del grupo que consiste de un alquilo C₁₋₆ opcionalmente sustituido, un cicloalquilo opcionalmente sustituido, un cicloalquenilo opcionalmente sustituido, un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido, un heterociclilo opcionalmente sustituido, un cicloalquil(C₁₋₆ alquilo) opcionalmente sustituido, un cicloalquenil(C₁₋₆ alquilo) opcionalmente sustituido, un aril(C₁₋₆ alquilo) opcionalmente sustituido, un heteroaril(C₁₋₆ alquilo) opcionalmente sustituido y un heterociclil(C₁₋₆ alquilo) opcionalmente sustituido; R² y R³ cada uno independientemente se selecciona del grupo que consiste de hidrógeno, halógeno, un C₁₋₆ alquilo opcionalmente sustituido y un C₁₋₆ haloalquilo opcionalmente sustituido; o R² y R³ junto con el carbono al cual R² y R³ se acoplan forman un cicloalquilo opcionalmente sustituido, un cicloalquenilo opcionalmente sustituido o un heterociclilo opcionalmente sustituido; R⁴ y R⁵ cada uno se selecciona independientemente del grupo que consiste de hidrógeno, halógeno, un C₁₋₆ alquilo opcionalmente sustituido y un C₁₋₆ haloalquilo opcionalmente sustituido; o R⁴ y R⁵ junto con el carbono al cual R⁴ y R⁵ se acoplan forman un cicloalquilo opcionalmente sustituido, un cicloalquenilo opcionalmente sustituido o un heterociclilo opcionalmente sustituido; R⁶, R⁷, R⁸ y R⁹ cada uno independientemente se selecciona del grupo que consiste de hidrógeno, halógeno, hidroxi, un alquilo opcionalmente sustituido, un alcoxi opcionalmente sustituido, un haloalquilo opcionalmente sustituido, una amina mono-sustituida opcionalmente sustituida y una amina di-sustituida opcionalmente sustituida; R¹⁰ es hidrógeno, halógeno, un alquilo opcionalmente sustituido o un cicloalquilo opcionalmente sustituido; R¹¹ es hidrógeno o un C₁₋₆ alquilo opcionalmente sustituido; y R¹² es hidrógeno, halógeno, un C₁₋₃ alquilo opcionalmente sustituido, un C₁₋₃ haloalquilo opcionalmente sustituido o un C₁₋₃ alcoxi opcionalmente sustituido; siempre que cuando R¹¹ sea hidrógeno o metilo, X¹ es NH, Y¹ y Z¹ cada uno es C, X² es O, A¹ es un fenilo, 2-fluorofenilo, o 2,6-difluorofenilo, tanto R² como R³ son metilo o uno de R² y R³ es hidrógeno y el otro de R² y R³ es metilo, y R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ y R¹⁰ cada uno es hidrógeno, entonces R¹ no podrá ser 2-hidroxietilo, 2-metilpropilo, 2-fluoro-2-metilpropilo, 3-fluoro-2-metilpropilo, 3-hidroxi-2-metilpropilo o 2-fluoro-3-hidroxi-2-metilpropilo. Reivindicación 43: Un compuesto seleccionado del grupo que consiste de los restos del grupo de fórmulas (2). Reivindicación 44: Un compuesto seleccionado del grupo que consiste de los compuesto de fórmula (3) y (4). Reivindicación 45: Un compuesto de la fórmula (5). Reivindicación 46: Un compuesto de la fórmula (6).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317254P | 2016-04-01 | 2016-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108011A1 true AR108011A1 (es) | 2018-07-04 |
Family
ID=59966438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100788A AR108011A1 (es) | 2016-04-01 | 2017-03-30 | Moduladores receptores de estrógenos |
Country Status (15)
Country | Link |
---|---|
US (5) | US20190142811A1 (es) |
EP (1) | EP3442971A4 (es) |
JP (2) | JP6926189B2 (es) |
KR (2) | KR20220071293A (es) |
CN (4) | CN113717170A (es) |
AR (1) | AR108011A1 (es) |
AU (3) | AU2017242027B2 (es) |
BR (1) | BR112018070161A2 (es) |
CA (1) | CA3017388C (es) |
IL (3) | IL295050A (es) |
MX (2) | MX2018011419A (es) |
RU (1) | RU2738646C2 (es) |
SG (1) | SG11201807708SA (es) |
TW (2) | TW202235418A (es) |
WO (1) | WO2017172957A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6905539B2 (ja) | 2016-02-05 | 2021-07-21 | インベンティスバイオ リミテッド ライアビリティ カンパニー | 選択的エストロゲン受容体分解剤およびその使用 |
CN113717170A (zh) | 2016-04-01 | 2021-11-30 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
CN111164063A (zh) | 2017-09-11 | 2020-05-15 | 里科瑞尔姆Ip控股有限责任公司 | 用于制备双环化合物的连续流动方法 |
JP2021503448A (ja) * | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | Lsz102及びリボシクリブを含む医薬組合せ |
US20220220107A1 (en) * | 2019-05-24 | 2022-07-14 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Crystal forms of acrylic acid derivatives, preparation method therefor and use thereof |
EP3993787A4 (en) * | 2019-08-06 | 2023-07-12 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS |
JP2022553833A (ja) * | 2019-11-04 | 2022-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬の塩及び形態 |
US20230042653A1 (en) * | 2019-12-20 | 2023-02-09 | Recurium Ip Holdings, Llc | Combinations |
MX2022007627A (es) * | 2019-12-20 | 2022-08-16 | Recurium Ip Holdings Llc | Combinaciones. |
US20230087941A1 (en) * | 2019-12-20 | 2023-03-23 | Recurium Ip Holdings, Llc | Combinations |
EP4069236A4 (en) * | 2019-12-20 | 2023-12-27 | Recurium IP Holdings, LLC | COMBINATIONS |
WO2021127042A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
IL297448A (en) * | 2020-04-22 | 2022-12-01 | Recurium Ip Holdings Llc | Preparation of a selective estrogen receptor complex |
WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
WO2022061242A1 (en) * | 2020-09-20 | 2022-03-24 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
WO2022133446A1 (en) * | 2020-12-16 | 2022-06-23 | Recurium Ip Holdings, Llc | Combinations |
JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
AU2022305957A1 (en) * | 2021-07-08 | 2024-01-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0749313A4 (en) | 1994-03-11 | 2001-10-24 | Lilly Co Eli | METHOD OF TREATING CONDITIONS ASSOCIATED WITH THE 5HT 2B RECEPTOR |
GB9604996D0 (en) | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
EP1438310B1 (en) | 2001-10-19 | 2006-12-20 | TransTech Pharma Inc. | Beta-carbolin derivatives as ptp-inhibitors |
US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
WO2006015035A1 (en) | 2004-08-02 | 2006-02-09 | Smithkline Beecham Corporation | Useful compounds for hpv infection |
WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
CA2656067C (en) | 2006-06-23 | 2014-08-12 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
EP2139476A1 (en) | 2007-04-13 | 2010-01-06 | PTC Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
TW201028414A (en) * | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
CA3184380A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
WO2010138706A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
EP2653468B1 (en) * | 2009-07-28 | 2016-02-24 | Ono Pharmaceutical Co., Ltd. | Bicyclic Compound and Use Thereof for Medical Purposes |
JP2013517272A (ja) | 2010-01-15 | 2013-05-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病化合物としてのオキサジアゾール・ベータ・カルボリン誘導体 |
EA020528B1 (ru) * | 2010-02-11 | 2014-11-28 | Бристол-Майерс Сквибб Компани | Макроциклы в качестве ингибиторов фактора xia |
US20130172320A1 (en) | 2010-02-18 | 2013-07-04 | Sarvajit Chakravarty | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
JP2013528223A (ja) | 2010-06-10 | 2013-07-08 | アラゴン ファーマシューティカルズ,インク. | エストロゲン受容体モジュレーターおよびその用途 |
EP2669279B1 (en) * | 2011-01-27 | 2017-01-11 | ONO Pharmaceutical Co., Ltd. | Bicyclic compound and use thereof for medical purposes |
CN102432608B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法 |
EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
NO2797921T3 (es) * | 2011-12-31 | 2018-02-03 | ||
EP2811997B1 (en) * | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
MX2014011217A (es) | 2012-03-20 | 2015-03-10 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno y sus usos. |
LT2872482T (lt) | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
EP2958907B1 (en) | 2013-02-19 | 2018-02-28 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
MX2015011132A (es) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
US9155727B2 (en) * | 2013-05-28 | 2015-10-13 | Astrazeneca Ab | Chemical compounds |
CA2932106A1 (en) | 2013-12-06 | 2015-06-11 | F. Hoffmann-La Roche Ag | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
CN104693211A (zh) | 2013-12-10 | 2015-06-10 | 南京明德新药研发股份有限公司 | 作为抗病毒剂的咪唑衍生物及其制药用途 |
UY35993A (es) * | 2014-02-12 | 2015-08-31 | Eolas Therapeutics Inc | Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina |
US9695166B2 (en) * | 2014-05-05 | 2017-07-04 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
WO2015173329A1 (en) | 2014-05-16 | 2015-11-19 | Actelion Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
KR20230035446A (ko) | 2014-06-27 | 2023-03-13 | 노그라 파마 리미티드 | 아릴 수용체 조정제, 및 그의 제조 및 사용 방법 |
NZ731344A (en) | 2014-10-09 | 2018-08-31 | Guangdong Raynovent Biotech Co Ltd | Hydroxyl purine compounds and applications thereof |
US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
EP3286164A4 (en) | 2015-04-21 | 2018-12-05 | Gtx, Inc. | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
EP3312184A4 (en) * | 2015-06-16 | 2019-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF |
JP6592197B2 (ja) * | 2015-11-12 | 2019-10-16 | 浙江海正薬業股▲ふん▼有限公司Zhejiang Hisun Pharmaceutical CO.,LTD. | アクリル酸誘導体、製造方法、および医薬としてのその使用 |
JP6905539B2 (ja) * | 2016-02-05 | 2021-07-21 | インベンティスバイオ リミテッド ライアビリティ カンパニー | 選択的エストロゲン受容体分解剤およびその使用 |
CN113717170A (zh) | 2016-04-01 | 2021-11-30 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
MX2018015179A (es) | 2016-06-10 | 2019-10-14 | Univ Tennessee Res Found | Ligandos degradadores selectivos del receptor de androgenos (sard) y metodos de uso de los mismos. |
WO2018001232A1 (zh) * | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
JP7050770B2 (ja) * | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
-
2017
- 2017-03-29 CN CN202111035485.4A patent/CN113717170A/zh active Pending
- 2017-03-29 MX MX2018011419A patent/MX2018011419A/es unknown
- 2017-03-29 EP EP17776574.0A patent/EP3442971A4/en active Pending
- 2017-03-29 AU AU2017242027A patent/AU2017242027B2/en active Active
- 2017-03-29 SG SG11201807708SA patent/SG11201807708SA/en unknown
- 2017-03-29 RU RU2018132037A patent/RU2738646C2/ru active
- 2017-03-29 WO PCT/US2017/024809 patent/WO2017172957A1/en active Application Filing
- 2017-03-29 CA CA3017388A patent/CA3017388C/en active Active
- 2017-03-29 IL IL295050A patent/IL295050A/en unknown
- 2017-03-29 KR KR1020227016946A patent/KR20220071293A/ko not_active Application Discontinuation
- 2017-03-29 BR BR112018070161-0A patent/BR112018070161A2/pt active Search and Examination
- 2017-03-29 IL IL285318A patent/IL285318B/en unknown
- 2017-03-29 JP JP2019503398A patent/JP6926189B2/ja active Active
- 2017-03-29 KR KR1020187030841A patent/KR102401841B1/ko active IP Right Grant
- 2017-03-29 US US16/086,434 patent/US20190142811A1/en not_active Abandoned
- 2017-03-29 CN CN202011582762.9A patent/CN112679495B/zh active Active
- 2017-03-29 CN CN201780033815.1A patent/CN109311870B/zh active Active
- 2017-03-29 CN CN202011582784.5A patent/CN112745316A/zh active Pending
- 2017-03-30 TW TW110145253A patent/TW202235418A/zh unknown
- 2017-03-30 AR ARP170100788A patent/AR108011A1/es unknown
- 2017-03-30 TW TW106110662A patent/TWI746535B/zh active
-
2018
- 2018-09-06 IL IL261654A patent/IL261654B/en unknown
- 2018-09-24 MX MX2022005780A patent/MX2022005780A/es unknown
-
2020
- 2020-05-05 US US16/866,995 patent/US10959989B2/en active Active
- 2020-05-05 US US16/867,017 patent/US11065234B2/en active Active
- 2020-05-05 US US16/866,900 patent/US11065233B2/en active Active
- 2020-12-22 AU AU2020294196A patent/AU2020294196B2/en active Active
-
2021
- 2021-07-06 US US17/305,369 patent/US20210330651A1/en active Pending
- 2021-08-04 JP JP2021127863A patent/JP2021176911A/ja active Pending
-
2022
- 2022-06-09 AU AU2022204025A patent/AU2022204025A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108011A1 (es) | Moduladores receptores de estrógenos | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR085958A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR089550A1 (es) | Compuestos quimicos | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR100775A1 (es) | Compuestos pesticidas y procedimientos relacionados con los mismos | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR101528A1 (es) | Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina | |
AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
AR098818A1 (es) | Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos | |
AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
AR099867A1 (es) | Compuestos imidazobenzotiazolo fusionados | |
AR098436A1 (es) | Compuestos tricíclicos de piperidina | |
AR095436A1 (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa | |
AR110514A1 (es) | Péptidos antimicrobianos |